Optimal T cell activation requires the delivery of costimulatory signals concomitant with T cell receptor engagement. CD28 is perhaps the most important and best-studied costimulatory receptor and is unique in its potency to augment IL-2 production. Ligation of CD28 increases cell proliferation and enhances cell survival as well as regulating production of multiple T cell–derived cytokines (1). Consistent with this, T cells from mice deficient in CD28 have impaired proliferative responses, make little IL-2, and have increased susceptibility to apoptosis (2–5). Although the importance of CD28 in T cell function is well established, many questions remain as to the mechanism by which CD28 mediates its biological effects.

CD28 possesses no intrinsic enzymatic activity; however, discrete regions within the cytoplasmic tail interact with intracellular adaptor proteins and enzymes to initiate signaling. Mutagenesis studies have identified two regions as being of particular importance. A tyrosine-based motif in the membrane proximal region of the cytoplasmic domain binds and activates PI-3 kinase, as well as interacting with the adaptor proteins Grb-2 and GADS (6–11). Less well characterized is a proline-based motif in the distal portion of the cytoplasmic domain. This region can interact with SH3 domain containing proteins including the Src family kinases Lck and Fyn to initiate signaling (7, 12).

Recent studies have been conflicting as to the importance of this motif in CD28 function. CD28 possesses no intrinsic enzymatic activity; however, discrete regions within the cytoplasmic tail interact with intracellular adaptor proteins and enzymes to initiate signaling. Mutagenesis studies have identified two regions as being of particular importance. A tyrosine-based motif in the membrane proximal region of the cytoplasmic domain binds and activates PI-3 kinase, as well as interacting with the adaptor proteins Grb-2 and GADS (6–11). Less well characterized is a proline-based motif in the distal portion of the cytoplasmic domain. This region can interact with SH3 domain containing proteins including the Src family kinases Lck and Fyn to initiate signaling (7, 12). Recent studies have been conflicting as to the importance of this motif in CD28-dependent responses, with some suggesting that it is critical for enhancing proliferation and IL-2 production. CD28 possesses no intrinsic enzymatic activity; however, discrete regions within the cytoplasmic tail interact with intracellular adaptor proteins and enzymes to initiate signaling. Mutagenesis studies have identified two regions as being of particular importance. A tyrosine-based motif in the membrane proximal region of the cytoplasmic domain binds and activates PI-3 kinase, as well as interacting with the adaptor proteins Grb-2 and GADS (6–11). Less well characterized is a proline-based motif in the distal portion of the cytoplasmic domain. This region can interact with SH3 domain containing proteins including the Src family kinases Lck and Fyn to initiate signaling (7, 12). Recent studies have been conflicting as to the importance of this motif in CD28-dependent responses, with some suggesting that it is critical for enhancing proliferation and IL-2 production.
secretion, whereas others indicate that it is dispensable for these functions but required for IL-4 production (13–16). Moreover, the requirement for this motif in the generation of a complex, in vivo immune response is unknown.

Given the importance of CD28 in the activation of naive T cells and that CD28 expression is itself regulated by cell activation, we generated a targeted knockin mouse expressing a mutation of the distal proline motif to determine its function. The CD28 P187,190A knockin (CD28–AYAA KI) mice thus express only the mutant form of CD28. In contrast with other experimental approaches, the genetic elements that regulate transcription are preserved and thus the mutant protein is expressed and regulated in a manner identical to the endogenous gene product. This strategy permits both in vitro and in vivo analysis of the functional consequences of the mutation with less concern that the results are the result of aberrant patterns of expression. In these studies, we find that the proline motif is critical for normal CD28-dependent regulation of IL-2 production and is absolutely required for antibody production and germinal center formation in vivo. Furthermore, we demonstrate that gene dosage is important in determining the phenotype of this mutation.

RESULTS

Generation of CD28 P187,190A knockin mice

To generate mice expressing mutant CD28 under endogenous regulatory control, we constructed a gene targeting vector containing exon IV of CD28 and flanking intronic sequences (Fig. 1 A). Specific mutations were introduced to substitute alanine for proline at residues 187 and 190, thus disrupting the motif responsible for interaction with SH3 domain–containing proteins (Fig. 1 B). This construct was transfected into murine embryonic stem cells and positive clones injected in C57BL/6 blastocysts. Germline transmission was verified by restriction mapping, Southern blotting, and sequencing (Fig. 1 C). To remove the Neomycin cassette, pups were crossed with mice carrying Cre-recombinase as a transgene under the control of the E2A promoter.
ARTICLE

To determine whether T cells carrying the mutant CD28-AYAA allele expressed the protein at a level comparable to the endogenous protein, CD28-deficient mice were isolated from CD28+/+, CD28AYAA/AYAA, and CD28−/− mice and stained for both CD4 and CD28. Shown are histograms of CD28 expression of each genotype after gating on CD4+ T cells. The expression of the mutant protein is equivalent to the endogenous protein.

Impaired IL-2 production in T cells from CD28-AYAA KI mice

CD28 is unique among costimulatory receptors in its potency with which it regulates IL-2. We therefore directly assayed the amount of IL-2 present in the culture supernatants of stimulated T cells from wild-type and CD28-AYAA knockin mice (Fig. 3 and Table I).

Consistent with previous reports, CD28+/− mice had an ~50% reduction in IL-2 (2). In contrast, there was no detectable IL-2 in cultures from CD28 AYAA−/− mice. Furthermore, the maximal IL-2 produced by CD28 AYAA/AYAA–expressing T cells was one third of that of CD28+/+ cells. IL-2 secretion was also absent in both the CD28 AYAA−/− and CD28 AYAA/AYAA mice after stimulation with PMA and anti-CD28 (unpublished data). However, all genotypes produced significant amounts of IL-2 after stimulation with PMA and ionomycin (Fig. 3).

Although there was a reduction in IL-2 secretion observed in both the CD28-deficient and CD28-AYAA mutant in response to
PMA + ionomycin as compared with controls, this was not consistently observed. Importantly, these data demonstrate that there is not a generalized impairment in IL–2 production that would account for the profound deficiency observed after stimulation with anti–CD3 and anti–CD28. Thus, normal regulation of IL–2 production by CD28 requires signals initiated by the PYAP motif.

To determine if the effect of the mutation was specific for IL–2 production or if it was representative of a more global defect in cytokine expression, we assayed a larger panel of T cell–derived cytokines (Table I). Mice expressing the mutant allele had a substantial reduction in the amount detected of several cytokines. These data suggest a more general requirement for the PYAP motif in CD28-dependent regulation of cytokine production.

Table I. Multiple cytokines are dependent on the proline motif of CD28

|        | CD28+/+   | CD28 AYAA/AYAA | CD28−/−   |
|--------|-----------|----------------|-----------|
| IL–2   | 22.63 / 503.92 | 19.30 / 30.00 | 3.69 / 5.03 |
| IL–4   | 1.46 / 22.15  | 2.78 / 11.47  | 0.45 / 0.60 |
| IL–5   | ND / 9.37   | 0.41 / 0.69   | ND / ND   |
| IL–10  | 1.52 / 33.01 | 5.78 / 17.93  | 1.26 / 1.85 |
| IL–12  | 1.19 / 5.79  | 0.47 / 2.09   | 1.39 / 0.15 |
| GMCSF  | 5.28 / 27.20 | 4.20 / 12.59  | ND / 1.97 |
| IFN–γ  | 3.16 / 1,086.72 | 17.12 / 245.16 | 0.67 / 0.71 |
| TNF–α  | 0.66 / 8.95  | 0.86 / 4.66   | 1.83 / 1.78 |

Splenocytes from the indicated genotypes were cultured with media alone, or activated with 1.0 μg/ml anti–CD3 alone or in combination with 1.0 μg/ml anti–CD28. Culture supernatants were harvested at 48 h and assayed for cytokine levels using the Th1/Th2 Bioplex multicytokine kit (BioRad Laboratories). All data are in pg/ml and the mean of triplicate samples presented.

**Figure 3.** Diminished IL–2 production in CD28 AYAA mice. Splenocytes were isolated from each of the indicated genotypes. Cultures were stimulated with graded doses of anti–CD3 alone or in the presence of 1.0 μg/ml anti–CD28 and IL–2 assayed in the culture supernatants after 48 h by ELISA. Representative data are shown from five independent experiments.

**Impaired proliferation in T cells from CD28–AYAA mice**

A fundamental property of CD28 costimulation is the augmentation of T cell proliferation, in particular to suboptimal levels of TCR engagement (19). To determine the effect of the P187,190A mutation on CD28–dependent proliferation, splenocytes from CD28+/+, CD28 AYAA−/−, CD28+−/− and CD28−/− mice were stimulated with increasing concentrations of anti–CD3 (0.01–10 μg/ml) alone or in combination with anti–CD28 mAb (1 μg/ml, clone PV–1) or CTLA4Ig (10 μg/ml) and proliferation was determined by [3H] thymidine incorporation (Fig. 4 A). T cells from CD28 AYAA−/− mice had a marked defect in proliferative response to anti–CD3 alone and to the combination of anti–CD3 + anti–CD28. This was not the result of a reduction in expression as the CD28+−/− and CD28−AYAA− cells expressed...
comparable levels of CD28 (Fig. 2). In contrast with the results seen with cells from the CD28-AYAA/− heterozygous mice, proliferation of T cells from homozygous CD28−/−AYAA/−AYAA mutant mice was near wild-type levels (Fig. 4 B). This reveals an important gene dosage effect, with a greater defect apparent at the lower expression levels seen in the heterozygous state.

We reasoned that the profound proliferative defective observed in cells from the heterozygous mutant might reflect limiting IL-2 availability. Although addition of exogenous IL-2 increased the proliferation of cells from both CD28−/− and CD28 AYAA/− mice, it did not fully restore it to the level observed in the CD28+/− cultures (Fig. 4 C). This suggests that the proliferative defect in both the CD28-deficient and CD28-AYAA mutant is partially, but not solely, the result of limiting IL-2.

To determine the response to physiologic engagement of the TCR and CD28 with natural ligand, we stimulated cells of each genotype with alloantigen in a mixed lymphocyte culture (Fig. 4 E). Both homozygous and heterozygous mutant cells failed to proliferate, whereas cells expressing wild-type CD28 mounted a robust proliferative response. In addition, neither homozygous nor heterozygous CD28-AYAA mutant mice proliferated after activation with PMA and anti-CD28 (Fig. 4 D). Importantly, all genotypes proliferated in response to PMA and ionomycin and had similar expression of CD69 after activation (Fig. 4 D and Fig. S2, available at http://www.jem.org/cgi/content/full/jem.20052230/DC1). Thus, there is a relative requirement for the C-terminal proline residues after activation by anti-CD3 and anti-CD28 that is partially overcome by increased expression levels, whereas there is an absolute requirement for

---

**Figure 4.** Impaired proliferation in cells from CD28 AYAA mice. (A and B) Splenocytes were isolated from each of the indicated genotypes and stimulated with graded doses of anti-CD3 alone, with 10 μg/ml CTLA4Ig or with 1.0 μg/ml anti-CD28. (C) Splenocytes were stimulated with 0.01 μg/ml anti-CD3 alone, with 1.0 μg/ml anti-CD3 and anti-CD28, or with 100 U/ml anti-CD3, anti-CD28, and exogenous IL-2. Proliferation was measured after an overnight pulse with tritiated thymidine initiated at 48 h. (D) Proliferation was measured after 48 h. (E) Splitenocytes of the indicated genotypes (R) were cocultured with irradiated allogeneic splenocytes (S) for 96 h and proliferation was determined by tritiated thymidine incorporation. Representative data are shown from a minimum of three independent experiments.
this motif for proliferation induced by alloantigen or by PMA and anti-CD28.

Proliferation was also determined by CFSE dye dilution. Splenocytes were loaded with CFSE and stimulated with anti-CD3 alone or in combination with anti-CD28. At 48, 72, and 96 h after stimulation, aliquots of cells were stained with anti-CD4–PE and analyzed by two-color flow cytometry. Presented in Fig. 5 is the percentage of CD4+ T cells that have undergone at least one cell division at 72 h. Representative histograms obtained from cultures stimulated with 0.01 μg/ml anti-CD3 alone (Fig. 5, left) or anti-CD3 + anti-CD28 (Fig. 5, right) are also shown. Markedly fewer cells expressing the mutant CD28 undergo cell division than cells expressing the wild-type allele, thus independently confirming the results obtained by thymidine incorporation. A similar pattern of results was observed at 48- and 96-h time points (unpublished data).

We consistently found that the homozygous CD28 AYAA mutant cells manifest a 1-log shift in the dose response to anti-CD3 as compared with control cultures (Fig. 4 B). In these experiments, endogenous CD80 and CD86 present on the APCs in the culture provided costimulation as indicated by the abrogation of proliferation after inclusion of CTLA4Ig. In addition, activation by alloantigen, which utilizes endogenous B7:CD28 interactions, was markedly impaired. This led us to hypothesize that differences in the level of receptor engagement between endogenous B7 and anti-CD28 mAb might be important in determining the consequence of the mutation. To investigate this, we stimulated splenocytes with anti-CD3 in the presence of CTLA4Ig to block endogenous costimulation and titrated in increasing amounts of anti-CD28 mAb (Fig. 6). In both the heterozygous and homozygous mutants, proliferation was markedly impaired at lower doses of anti-CD28. The effect was even more profound at submitogenic doses of anti-CD3 (unpublished data). Thus, at limiting levels of antigen receptor and CD28 engagement, signaling through the proline motif is critical for T cell proliferation.

**Up-regulation of BclXL expression**

In addition to regulating cell proliferation and cytokine production, CD28 costimulation enhances cell survival.
One mechanism by which this occurs is up-regulation of the antiapoptotic protein Bcl-XL (20). Previous work has determined this to be downstream of PI-3 kinase activation and requires the tyrosine-based motif in the proximal portion of the cytoplasmic domain of CD28 (21–24). We had previously demonstrated that the expression pattern of Bcl-XL was preserved in CD28-deficient T cells retrovirally transduced with the CD28-AYAA mutation (14). However, in that system, the T cells had been previously activated to facilitate gene transduction. We therefore tested whether CD28-dependent regulation of Bcl-XL expression was intact in naive T cells isolated from the CD28-AYAA KI mice. As expected, CD28-deficient T cells failed to increase BCL-XL expression in response to anti-CD28 costimulation. Both CD28 \(+/-\) and CD28 AYAA/− T cells up-regulated BCL-XL, although the increase in the AYAA mutant cells was less than that of the CD28 \(+/-\) cells (Fig. 7). Thus, consistent with our previous findings and work demonstrating a strict requirement for the upstream tyrosine-based motif in regulation of Bcl-XL, up-regulation was not absolutely dependent on the proline-based motif (14, 23). However, there does appear to be some contribution to Bcl-XL expression mediated by signaling initiated by the proline motif. Nonetheless, these data do demonstrate that mutation of the C-terminal proline motif does not globally impair CD28 function.

CD28-AYAA KI mice manifest impaired humoral immunity in vivo

The aforementioned experiments demonstrate the importance of the PYAP motif in the regulation of T cell proliferation and IL-2 production in vitro. However, these findings may not accurately recapitulate events in vivo. The CD28-AYAA knockin mice provide a powerful tool to determine the role of signaling pathways initiated by the PYAP motif during an in vivo T cell–dependent immune response.

Experimental allergic airway inflammation is a model of a Th2 immune response characterized by an eosinophilic inflammatory cell infiltrate in the lung (25). Mice treated with soluble inhibitors of B7 or CD28-deficient mice develop no inflammatory or antibody response (26–28). To determine if the PYAP motif of CD28 was required, CD28-AYAA KI or control mice were sensitized and challenged with OVA.
Representative data are shown from three independent experiments. Of a 44-kD protein, Tp44, on the surface of human T cells CD28 was first described in studies reporting that ligation

**DISCUSSION**

CD28 was first described in studies reporting that ligation of a 44-kD protein, Tp44, on the surface of human T cells augmted proliferation induced by PHA or alloantigen and IL-2 production (19, 29). Numerous papers have been subsequently published characterizing the profound effect of CD28 on T cell function in particular and its importance in regulating IL-2 expression and proliferation. Later work identified CD28 as a determinant of cell survival and metabolism through regulation of the antiapoptotic protein Bcl-X 

Despite the aforementioned profound in vitro defects, mice heterozygous for the mutant allele developed similar airway inflammation as wild-type control mice, as assessed by bronchoalveolar lavage and histology (Fig. 8).

In contrast with the normal tissue inflammation observed in the mutant mice, there was a marked decrease in OVA-specific antibody relative to wild-type controls (Fig. 9, A and B). This was accompanied by a failure of the CD28 AYAA KI mice to develop germinal centers (GCs) in the spleen as determined by staining with PNA and anti-IgD (Fig. 9, C–E). Mice expressing mutant CD28 had a 5-fold reduction in GCs per 10× field or a >20-fold reduction in total GCs per section as compared with mice expressing wild-type CD28. This was evident in both heterozygous and homozygous CD28-AYAA KI mice. Thus, there is an absolute requirement for the PYAP motif in the development of OVA-specific antibodies and GC formation in vivo. Furthermore, this mutation dissociates specific CD28-dependent elements of the immune response, as the CD28-AYAA were able to mount a normal inflammatory response in the tissue, yet failed to produce a humoral response, whereas wild-type mice have both elements and CD28-deficient mice have neither.

**Figure 8.** Allergic airway inflammation is intact in CD28-AYAA mice. Mice of each genotype were systemically sensitized to OVA and given an inhaled challenge. 72 h after challenge, the BAL and lung tissue were collected for analysis. There was no difference in cell recovery or differential analysis of the BAL fluid obtained from the wild-type CD28 AYAA mice. Similarly, histologic examination revealed inflammation in both wild-type and CD28 AYAA mutant mice, but not CD28−/− mice. Representative data are shown from three independent experiments.

Although it is clear that CD28 activates multiple signaling pathways, the contribution of each to the downstream effector functions of CD28 remains controversial. Much of the conflicting data may arise from the nature and differences in the experimental systems that have been used. Many of these studies have used transformed cell lines that have intrinsic abnormalities in proliferation and survival, making extrapolation to primary cells difficult. To circumvent this problem, several groups have used retroviral gene transfer into primary cells; however, this requires activation of the T cell to facilitate infection. Therefore, the cells are no longer naive (13, 14).

Given that CD28 is most important in the initial activation of resting naive T cells, this approach is also problematic. In addition, expression levels of the retrovirally transduced gene are variable and not regulated in a manner analogous to the endogenous gene product. Although reconstitution of the CD28-deficient mice with specific transgenes avoids the problem of cell activation and therefore allows for the study of naive cells, the use of heterologous promoters alters the regulation of expression. Thus, none of these experimental approaches faithfully recapitulate endogenous CD28. In contrast, the knockin mouse we have described allows the study of CD28 in naive T cells under conditions in which expression is correctly regulated by endogenous genetic elements.

The C-terminal proline motif can bind SH3 domain containing proteins including the Src family kinases Lck and Fyn, the Tec kinase Itk, and the adaptor protein Grb2 (7, 11, 12, 15, 32–34). Knockin mice expressing a single copy of CD28 containing a mutation of this region had a profound defect in IL-2 production and proliferation after activation with anti-CD3 and anti-CD28, demonstrating that this motif is critical in the regulation of these functions. Higher expression levels present in homozygous mutant mice restored proliferation to near wild-type levels, but IL-2 secretion remained severely impaired. In contrast, activation by alloantigen in which both the TCR and CD28 are engaged by endogenous ligand failed to induce proliferation in cells from either homozygous or heterozygous mutant mice. Thus, under activation conditions that more closely model physiologic engagement of CD28, this motif is critical regardless of expression level. Similarly, there was an absolute defect in proliferation and IL-2 secretion after activation by PMA + anti-CD28 in both heterozygous and homozygous mutant mice, confirming a requirement for this motif in some CD28-dependent signaling pathways.

**Figure 8.** Allergic airway inflammation is intact in CD28-AYAA mice.
The importance of this region is consistent with early studies in cell lines in which deletion of this region abrogated CD28-dependent IL-2 production (35–37), and are supportive of some studies using retroviral gene transfer (14, 15). However, recent publications examining this have been conflicting. Andres et al. transduced bone marrow cells from CD28-deficient mice with a series of mutant CD28 constructs and demonstrated that no single motif was absolutely required for proliferation and IL-2 production; however, IL-4 production did require the C-terminal proline residues (13). Tai et al. addressed this question by reconstituting CD28-deficient mice with mutant CD28 transgenic constructs controlled by the CD2 promoter (16). These studies demonstrated that the proline motif is required for CD28-dependent IL-2 production after stimulation with PMA and anti-CD28, as well as for the generation of regulatory T cells in vivo independent of the effect on IL-2. Our data are in agreement with a requirement for the C-terminal proline residues for the normal regulation of IL-2 production and proliferation by CD28. Importantly, our data provide an explanation for the reported differences in these datasets. Our data clearly demonstrate that higher expression levels, which might be achieved in some retrovirally transduced cells, under some experimental conditions may mask the requirement for this motif. Furthermore, we demonstrate that there is an absolute requirement for an intact PYAP motif when the cells are activated by PMA and anti-CD28 or by alloantigen, whereas activation by anti-CD3 and anti-CD28 is less dependent on the distal proline residues. Thus, differences in both expression levels and activation conditions account for the reported discrepancies in the requirement for this region in the regulation of proliferation and IL-2.

Given the defects in proliferation and cytokine secretion, we examined signaling pathways activated after T cell activation. We saw no difference in either total protein tyrosine phosphorylation or ERK phosphorylation after stimulation with anti-CD3 and anti-CD28 antibody in primary T cells from either wild-type or mutant mice (Fig. S3, available at http://www.jem.org/cgi/content/full/jem.20052230/DC1). Although other reports have demonstrated CD28-dependent effects in these assays, we failed to reproduce these observations (34, 38). It is possible that differences in experimental systems may account for this discrepancy.

In vivo, CD28 is engaged by CD80 or CD86 on the surface of an APC. Recent studies suggest that the B7:CD28 interaction may be monovalent and therefore may not induce
a high degree of receptor cross-linking (39, 40). In contrast, saturating doses of anti-CD28 mAb are likely to lead to extensive cross-linking and may activate signaling pathways that would not be activated under more physiologic conditions. Consistent with this hypothesis, we found that the proliferative defect in the CD28-AYAA mutant cells was more profound under conditions of endogenous costimulation or limiting amounts of mAb.

A large body of work has focused on the proximal motif centered around the tyrosine at position 170 (Y170), which is critical for PI-3 kinase activation as well as binding the adaptor proteins Grb2 and GADS through their SH2 domain (8, 9, 11, 41). Controversy exists as to the precise role of CD28-dependent activation of PI-3 kinase in the regulation of proliferation and IL-2 secretion. Recent studies have provided some resolution, with several confirming the importance of this pathway in induction of Bcl-XL (14, 23). More recently, it has been demonstrated that mutation of this motif abrogated CD28-dependent regulation of IL-2 transcription, yet leaves the posttranscriptional regulation of IL-2 mRNA stability intact (42). Thus, it would appear that distinct signaling cascades are responsible for the coordinated regulation of IL-2 secretion by CD28.

In contrast with the marked defect in proliferation and cytokine production, expression of Bcl-XL was less profoundly altered in the CD28-AYAA mutant cells. In studies performed by either retroviral gene transfer or transgenic mice, a point mutation of Y170 abolished Bcl-XL expression, yet left IL-2 intact (14, 23). Similarly, using chimeric constructs in human T cells, Parry et al. demonstrated that the membrane proximal domain of CD28 was required for Bcl-XL induction, although both proximal and distal regions were necessary for normal IL-2 production (24). The relative preservation of Bcl-XL expression in the CD28-AYAA knockin mutant demonstrates that the mutation has not globally impaired CD28 function and is consistent with a requirement for the proximal tyrosine based motif as the major pathway by which CD28 regulated Bcl-XL expression.

In contrast with reconstitution by retroviral gene transfer or transgenic constructs under the control of a heterologous promoter, the knockin mouse we have generated allows for determination of the effect of the mutation in vivo, with less likelihood that that aberrant expression patterns influence the result. Given previous data suggesting that this motif was critical in the generation of a Th2 response, we examined their response in a model of allergic airway inflammation. This model is CD28-dependent and leads to a Th2-type inflammatory response with recruitment of eosinophils to the lung and the generation of OVA-specific IgG1 and IgE (26, 27, 43). Despite the proliferative and cytokine defects observed in vitro, the inflammatory response of the mutant mice was indistinguishable from wild type as assessed by histology and analysis of the cellular composition of the BAL fluid. The ability to recruit inflammatory cells to the lung after the inhaled antigen challenge suggests that the initial priming and clonal expansion of antigen-specific T cells remained intact in the mutant mice. Nonetheless, it remains possible that Th2 development was impaired despite the presence of eosinophils in the airways (44, 45).

Although the cellular immune response appeared grossly intact, the humoral response was significantly impaired in homozygous and heterozygous CD28-AYAA mutant mice. There was a drastic reduction in OVA-specific IgG1 in both homozygous and heterozygous mutant mice. This was accompanied by a failure of the mutant mice to form germinal centers in the spleen. Thus, these aspects of CD28 function are absolutely dependent on an intact PYAP motif. A requirement for B7-CD28 in humoral responses was first noted in the characterization of mice expressing a soluble CTLA4Ig transgene as well as in the characterization of CD28-deficient mice (46, 47). This may be secondary to the loss of specific cognate interactions between T and B cells, as well as defective cytokine and/or chemokine production by the mutant T cells. Although a relative deficiency in IL-4 secretion might account for the lack of Th2 Ig isotypes, it is unlikely to lead to a complete failure to develop germinal centers. However, there is an intimate relationship between B7:CD28 and CD40:CD40L interactions (48, 49). A failure to up-regulate CD40L on the mutant T cells could account for the decreased antibody and GC formation, particularly in combination with a relative deficiency in IL-4 (50). Recent data suggests that CD28 regulates the expression of OX40 on T cells and that the combined action of CD28 and OX40 is important in the expression of CXCR5 on T cells (51, 52). This in turn may regulate the migration of T cells into the B cell follicle to support the GC reaction. Some investigators have proposed that the T cells supporting the GC reaction may in fact be a novel class of T helper cells (53). The requirement for costimulation in the development and function of these cells is only beginning to be examined.

In summary, our data demonstrates that the C-terminal proline motif is critical for normal regulation of proliferation and IL-2 production by CD28 in resting naive primary T cells. We also have shown that there is an important gene dosage effect in the mutant phenotype as a twofold change in the expression level of the mutant protein was sufficient to essentially normalize cell proliferation, but not IL-2 production. Furthermore, in vivo, this motif discriminates between specific elements of CD28 that regulate cellular and humoral aspects of the immune response in vivo, as it is essential for antibody production and GC formation, but not cell-mediated inflammation. This aspect, in particular, suggests that selective manipulation of this portion of the CD28 signal transduction pathway might be of potential therapeutic value by inhibiting humoral responses while preserving cellular immunity.

**MATERIALS AND METHODS**

**Generation of CD28-AYAA knockin construct.** A 14-Kb EcoRI fragment containing exon IV of CD28 was cloned from a mouse genomic BAC library (Incyte Genomics). This was digested with BamH1 and a LoxP site–flanked Neomycin resistance cassette was inserted into the 5′ BamH1 site. The 1.7-Kb short arm was generated by PCR spanning from the BamH1 site to the EcoRI site upstream and cloned 5′ to the Neomycin cassette. The resultant
construct contained two new EcoRI sites flanking the Neomycin cassette as indicated in Fig. 1. Oligonucleotide-directed site-specific mutagenesis was performed to generate specific base pair changes (GCC to GCC and CCT to GCT) resulting in a final sequence that substituted alanine for proline at positions 187 and 190. The sequence of the entire exon was verified by direct sequence analysis. The construct was transfected into 129/Sv embryonic stem cells (line RW4, provided by the Siteman Cancer Center, Washington University, St. Louis) and neomycin resistant clones were screened for homologous recombination by Southern blotting of BglII- and EcoRI-digested DNA using 5' and 3' external probes, respectively (Fig. 1 C). The mutation was confirmed by direct sequencing of exon IV after PCR amplification, as well as by restriction digestion with HaeIII, as the mutation results in the generation of a new HaeIII site (unpublished data). Germline transmission was verified by Southern blotting using both 5' and 3' external probes. In addition, the presence of the mutation was confirmed by both restriction digest and direct sequence analysis.

Mice. C57BL/6 mice were purchased from The Jackson Laboratory. CD28-deficient mice on the C57BL/6 background were originally obtained from C. Thompson (University of Pennsylvania, Philadelphia, PA). All mice were bred and housed under specific pathogen-free conditions at Washington University School of Medicine. All animal experimentation has been approved by Institutional Animal Use and Care Committee at Washington University School of Medicine.

Antibodies. Anti-CD3 (145-2c11 hamster IgG) and all fluorescently conjugated antibodies were purchased from BD Biosciences or eBioscience. For staining, fluorescently conjugated anti-CD28 (clone 37.5.1) was used. For stimulation, anti-CD28 clone PV-1 (Southern Biotechnology Associates, Inc.) was used. Anti-Bcl-XL, clone 7B2.5 ascites (mouse IgG3) was provided by L. Boise (University of Miami, Miami, FL).

RT-PCR. Total RNA was isolated from wild-type or mutant thymocytes using TRIzol reagent (Invitrogen). RT-PCR was performed using primers specific for exons I and IV of CD28. The product was purified, digested with HaeIII, and electrophoresed on a 15% polyacrylamide gel. The bands were visualized after staining with ethidium bromide.

[3H] incorporation assays. Splenocytes were isolated by density gradient centrifugation, plated at 10⁶ cells per well of a 96-well plate, and stimulated as indicated for each experiment. After 48 h of stimulation, the plates were pulsed with tritiated thymidine (1 μCi/well) overnight and harvested the following morning. For the mixed lymphocyte reaction, 5 × 10⁵ splenocytes of each genotype were cocultured with an equal number of BALB/c splenocytes that had been γ-irradiated (2,000 rad). After 96 h of stimulation, the cultures were pulsed with tritiated thymidine and harvested the following morning. Incorporated thymidine was determined by liquid scintillation counting. All conditions were plated in quadruplicate and the mean ± the standard deviation presented. All experiments have been replicated a minimum of three times and representative data are presented.

CFSE assays. Splenocytes were isolated and incubated at a concentration of 5.0 × 10⁶ cells/ml with 5 μM CFSE in 1x PBS + 5% FCS for 5 min at room temperature. After washing three times with 1x PBS, the cells were resuspended in media at 2.0 × 10⁶/ml and stimulated with anti-CD3, anti-CD28, and CTLA-4-Ig as described. Aliquots of cells were stained with PE-conjugated anti-CD4-MAb and the intensity of CFSE fluorescence of the CD4+ cells determined by two-color flow cytometry. Unstimulated cells were assayed simultaneously to determine the fluorescence intensity of unirradiated cells. All analysis was done using a FACScalibur flow cytometer with CELLQuest Software (Becton Dickinson Corporation).

Cytokines. Splenocytes were isolated and stimulated as described for the proliferation assays. After 48 h, culture supernatants were collected and assayed for IL-2 using the Quantikine murine IL-2 ELISA kit as per the manufacturer’s protocol (R&D Systems). Additional cytokines were assayed using the Bioplex murine Th1/Th2 panel as per the manufacturer’s direction (BioRad Laboratories).

Flow cytometry. CD28 expression of thymocytes or splenocytes was determined by staining with anti-CD4–FITC and anti-CD28–PE or isotype controls and analyzed on a FACSCalibur flow cytometer using CELLquest software (Becton Dickinson). Similarly, CD69 expression was determined on resting or activated CD4+ T cells by two-color flow cytometric analysis using anti-CD4–FITC and PE-conjugated anti-CD69. Bcl-XL expression was determined by intracellular staining as previously described (14).

Induction of allergic airway inflammation. Mice were immunized i.p. on days 0 and 7 with 8 μg OVA absorbed to 2 mg alum (Sigma-Aldrich) as previously described (25, 54). On day 14, the mice were intranasally challenged with 2% OVA and specimens collected on the third day after challenge. Bronchoalveolar lavage (BAL) was performed by intratracheal installation of 1% BSA in PBS. Cell differentials were performed on cytospin preparations stained with a modified Wright-Geimsa stain. For histology, the lungs were inflated with neutral buffered formalin to 25 cm of water pressure and fixed overnight. Samples were progressively dehydrated in ethanal and processed for sectioning and HE staining. Serum was collected at the time the mice were killed and antigen-specific immunoglobulin titer were determined by specific ELISA as previously described (28). Splenocytes were also harvested and frozen in OCT compound on dry ice. Frozen sections were prepared, fixed in acetone, and stained with PNA-biotin and rat anti-mouse IgD followed by detection with AP-streptavidin and goat anti-rat IgG(H+L)-HRP to detect GCs. Multiple sections were examined and the number of GCs/10X field were determined as well as the total number of GCs per section counted.

Online supplemental material. To determine whether the mutation altered the regulation of CD28 expression after T cell activation, cells were stimulated and CD28 expression was determined by flow cytometry (Fig. S1). Similarly, CD69 expression was assessed in wild-type and mutant T cells after activation (Fig. S2). Protein tyrosine phosphorylation and ERK phosphorylation was assessed in wild-type and mutant T cells by Western blotting (Fig. S3). Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20052230/DC1.

The generation of the targeting vector, screening of the ES cells, and mice and RT-PCR analysis of CD28 mRNA was performed by D. Shah. Germinal center staining and analysis was performed by C. Deppong. T. Juehne, T. Bricker, and C. Rose aided in the allergic airway inflammation experiments and breeding of the mice. J. Lin performed the biochemical assays. The remaining assays were performed by L. Friend. The authors would like to thank R. Arch, A. Shaw, and T. Ley for help throughout this project. We also thank R. McCarthy and M. White for skilled ES cell injection work. We thank L. Boise for anti-Bcl-XL antibody and M. Bessler for E2A-Cre mice on the C57BL/6 background. We would like to thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri, for the use of the Embryonic Stem Cell Core that provides transfection and ES cell culture service.

This research is supported in part by grants from the NIH (HL062683 to J.M. Green). C. Deppong is supported by NIH training grant no. T32 HL07317. L.D. Friend is supported through a fellowship by the Ford Foundation. The Siteman Cancer Center is supported in part by NCI Cancer Center Support grant no. P30 CA91842. The authors have no conflicting financial interests.

Submitted: 4 November 2005
Accepted: 24 July 2006

REFERENCES
1. Sharpe, A.H., and G.J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2:116–126.
2. Shahinian, A., K. Pfeffer, K.P. Lee, T.M. Kündig, K. Kishihara, A. Wakeham, K. Kawai, P.S. Ohashi, C.B. Thompson, and T.W. Mak.
9. Pagès, F., M. Ragueneau, S. Klasen, M. Battifora, D. Couez, and C.B. Thompson. 1994. Absence of B7-dependent responses in CD28-deficient mice. *Immunity*. 1:501–508.

10. Stein, P.H., J.D. Fraser, and A. Weiss. 1994. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T cell costimulation. *Proc. Natl. Acad. Sci. USA*. 92:8891–8895.

11. Kim, H.-H., M. Tharayil, and C.E. Rudd. 1998. Growth factor receptor-α6b2 protein 2SH/3SH domain binding to CD28 and its role in -alpha-signaling. *J. Biol. Chem.* 273:296–301.

12. zur Hausen, J.D., P. Burn, and K.E. Amrein. 1997. Co-localization of Lyn with CD3 complex, CD45 or CD28 depends on different mechanisms. *Eur. J. Immunol.* 27:2643–2649.

13. Andres, P.G., K.C. Howland, A. Nirula, L.P. Kane, L. Barron, D. Drensek, A. Sadra, J. Imboden, A. Weiss, and A.K. Abbas. 2004. Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiation. *Nat. Immunol.* 5:435–442.

14. Burr, J.S., N.D.L. Savage, G.E. Messah, S.L. Cacouz, R.H. Arch, and J.M. Green. 2001. Cutting edge: distinct motifs within CD28 regulate T cell proliferation and induction of Bcl-αL. *J. Immunol.* 166:5331–5335.

15. Holdorf, A.D., J.M. Green, S.D. Levin, M.F. Denny, D.B. Straus, V. Link, P.S. Changhien, P.M. Allen, and A.S. Shaw. 1999. Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation. *J. Exp. Med.* 190:375–384.

16. Tai, X., M. Cowan, L. Feigenbaum, and A. Singer. 2005. CD28 co-stimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. *Nat. Immunol.* 6:152–162.

17. Tremml, G., C. Dominguez, V. Rosti, Z. Zhang, P.P. Pandolfi, P. Keller, and M. Besler. 1999. Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. *Blood*. 94:2945–2954.

18. Lakso, M., J.G. Pichcl, J.R. Gorman, B. Sauer, Y. Okamoto, E. Lee, F.W. Alt, and H. Westphal. 1996. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. *Proc. Natl. Acad. Sci. USA*. 93:5860–5865.

19. Gmituder, H., and W. Leslauer. 1984. A 45-kDa human T cell membrane glycoprotein functions in the regulation of cell proliferative responses. *Eur. J. Biochem.* 142:153–160.

20. Bone, L.H., A. Merton, P.J. Noel, C.H. June, M.A. Accavitti, T. Lindsten, and C.B. Thompson. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of the Bcl-x. *Immunity*. 3:87–98.

21. Dahl, A.M., C. Klein, P.G. Andres, C.A. London, M.P. Lodge, R.C. Mulligan, and A.K. Abbas. 2000. Expression of Bcl-αL restores cell survival, but not proliferation and effecter differentiation, in T cells from CD28-deficient mice. *J. Exp. Med.* 191:3031–3038.

22. Jones, R.G., M. Parsons, M. Bonnard, V.S. Chan, W.C. Yeh, J.R. Woodgett, and P.S. Ohashi. 2000. Protein kinase B regulates T lymphocyte survival, nuclear factor kB activation, and Bcl-x(L) levels in vivo. *J. Exp. Med.* 191:1721–1734.

23. Okkenhaug, K., L. Wu, K.M. Garza, J. La Rose, W. Khoo, B. Odermatt, T.W. Mak, P.S. Ohashi, and R. Rottapel. 2001. A point mutation in CD28 distinguishes proliferative signals from survival signals. *Nat. Immunol.* 2:325–332.

24. Parry, R.V., C.A. Rumbley, H.L. Vandenbergh, C.H. June, and J.L. Riley. 2003. CD28 and inducible costimulatory protein Src homol-2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. *J. Immunol.* 171:166–174.

25. Kung, T.T., H. Jones, G.K. Adams III, S.P. Umland, W. Kreutner, R.W. Egan, R.W. Chapman, and A.S. Wattnick. 1994. Characterization of a murine model of allergic pulmonary inflammation. *Int. Arch. Allergy Immunol.* 105:83–90.

26. Harris, N., C. Campbell, G. Le Gros, and F. Ronchese. 1997. Blockade of CD28/CTLA4-Hy1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. *J. Exp. Immunol.* 27:155–161.

27. Keane-Myers, A., W.C. Gause, P.S. Linsley, S.J. Chen, and M. Wills-Karp. 1997. B7-CD28/CTLA4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. *J. Immunol.* 158:2042–2049.

28. Burr, J.S., L.H. Vandenbergh, and J.M. Green. 2001. CD28 and CTLA4 coordinate regulate airway inflammatory cell recruitment and T helper cell differentiation after inhaled allergen. *Am. J. Respir. Cell Mol. Biol.* 24:563–568.

29. Moretta, A., G. Pantaleo, M. Lopez-Botet, and L. Moretta. 1985. Involvement of T44 molecules in an antigen-independent pathway of T cell activation. Analysis of the correlations to the T cell antigen–receptor complex. *J. Exp. Med.* 162:823–838.

30. Frawirth, K.A., J.L. Riley, M.H. Harris, R.V. Parry, J.C. Ruthrell, D.R. Flas, R.L. Ehstrom, C.H. June, and C.B. Thompson. 2002. The CD28 signaling pathway regulates glucose metabolism. *Immunity*. 16:769–777.

31. Byrne, M.H., L.H. Vandenbergh, and C.B. Thompson. 1995. CD28 and apoptosis. *Curr. Opin. Immunol.* 7:620–625.

32. Marengere, L.E., K. Okkenhaug, A. Clavreul, D. Cacouz, S. Gibson, G.B. Mills, T.W. Mak, and R. Rottapel. 1997. The SH3 domain of Itk/Ent binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28. *J. Immunol.* 159:3220–3229.

33. Okkenhaug, K., and R. Rottapel. 1998. Ghr2 forms an inducible protein–protein complex with CD28 through a Src homology 3 domain–proline interaction. *J. Biol. Chem.* 273:2194–2120.

34. Carey, K.D., T.J. Dillon, J.M. Schmitt, A.M. Baird, A.D. Holdorf, D.B. Straus, A.S. Shaw, and P.J. Stork. 2002. CD28 and the tyrosine kinase lck stimulate mitogen-activated protein kinase activity in T cells via inhibition of the small G protein Rap1. *Mol. Cell. Biol.* 20:8409–8419.

35. Barz, C., T. Nagel, K.E. Trutt, and J.B. Imboden. 1998. Mutational analysis of CD28-mediated costimulation of Jun-N-terminal kinase and IL-2 production. *J. Immunol.* 161:5366–5372.

36. Nagel, T.J., J.R. Keir, and B. Manger. 2000. Co-stimulation of IL-2 production by CD28 is independent of tyrosine-based signaling motifs in a murine T cell hybridoma. *Eur. J. Immunol.* 30:1632–1637.

37. Trutt, K.E., T. Nagel, L.F. Suen, and J.B. Imboden. 1996. Structural requirements for CD28-mediated costimulation of IL-2 production in Jurkat T cells. *J. Immunol.* 156:4539–4541.

38. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia. 1999. T lymphocyte costimulation mediated by reorganization of membrane microdomains. *Science*. 283:680–682.

39. Collins, A.V., D.W. Brodie, R.J. Gilbert, A. Iaboni, R. Mant-Sancho, B. Walse, D.I. Stuart, P.A. van der Merwe, and S.J. Davis. 2002. The interaction properties of costimulatory molecules revisited. *Immunity*. 17:201–210.
40. Evans, E.J., R.M. Esnouf, R. Manso-Sancho, R.J. Gilbert, J.R. James, C. Yu, J.A. Fennelly, C. Vowles, T. Hanke, B. Walse, et al. 2005. Crystal structure of a soluble CD28-Fab complex. Nat. Immunol. 6:271–279.

41. King, P.D., A. Sadra, J.M. Teng, R.L. Xiao, A. Han, A. Selvakumar, A. August, and B. Dupont. 1997. Analysis of CD28 cytoplasmic tail tyrosine residues as regulators and substrates for the protein tyrosine kinases, EMT and LCK. J. Immunol. 158:580–590.

42. Sanchez-Lockhart, M., E. Marin, B. Graf, R. Abe, Y. Harada, C.E. Sedwick, and J. Miller. 2004. Cutting edge: CD28-mediated transcriptional and posttranscriptional regulation of IL-2 expression are controlled through different signaling pathways. J. Immunol. 173:7120–7124.

43. Harris, N., R. Peach, J. Naemura, P.S. Linsley, G. Le Gros, and F. Ronchese. 1997. CD80 costimulation is essential for the induction of airway eosinophilia. J. Exp. Med. 185:177–182.

44. Hogan, S.P., A. Mould, H. Kikutani, A.J. Ramsay, and P.S. Foster. 1997. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J. Clin. Invest. 99:1329–1339.

45. Kopf, M., G. Le Gros, M. Bachmann, M.C. Lamers, H. Blauethmann, and G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 362:245–248.

46. Paccual, M., G. Steiger, S. Sadallah, J.P. Paccaud, J.L. Carpenterier, R. James, and J.A. Schifferli. 1994. Identification of membrane-bound CR1 (CD35) in human urine: evidence for its release by glomerular podocytes. J. Exp. Med. 179:889–899.

47. Ferguson, S.E., S. Han, G. Kelsoe, and C.B. Thompson. 1996. CD28 is required for germinal center formation. J. Immunol. 156:4576–4581.

48. Ding, L., J.M. Green, C.B. Thompson, and E.M. Shevach. 1995. B7/CD28-dependent and -independent induction of CD40 ligand expression. J. Immunol. 155:5124–5132.

49. Roy, M., A. Aruffo, J. Ledbetter, P. Linsley, M. Kehry, and R. Noelle. 1995. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25:596–603.

50. Reiter, R., and K. Pfeffer. 2002. Impaired germinal centre formation and humoral immune response in the absence of CD28 and interleukin-4. Immunology. 106:222–228.

51. Walker, L.S., A. Gulbranson-Judge, S. Flynn, T. Brocker, C. Raykundalia, M. Goodall, R. Forster, M. Lipp, and P. Lane. 1999. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J. Exp. Med. 190:1115–1122.

52. Walker, L.S., A. Gulbranson-Judge, S. Flynn, T. Brocker, and P.J. Lane. 2000. Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40. Immunol. Today. 21:333–337.

53. Kim, C.H., L.S. Rott, J. Clark-Lewis, D.J. Campbell, L. Wu, and E.C. Butcher. 2001. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center–localized subset of CXCR5+ T cells. J. Exp. Med. 193:1373–1381.

54. Kimzey, S.L., P. Liu, and J.M. Green. 2004. Requirement for CD28 in the effector phase of allergic airway inflammation. J. Immunol. 173:632–640.